Santen Pharmaceutical (OTCMKTS:SNPHY) Sets New 52-Week High – Here’s Why

Shares of Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) hit a new 52-week high on Wednesday . The company traded as high as $13.8475 and last traded at $13.4450, with a volume of 502 shares trading hands. The stock had previously closed at $13.23.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, Santen Pharmaceutical presently has an average rating of “Hold”.

Santen Pharmaceutical Stock Performance

The stock has a market cap of $4.33 billion and a PE ratio of 0.10. The firm has a fifty day moving average price of $11.63 and a 200 day moving average price of $11.18.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.